Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase III, double blind (observer-blind), randomized, controlled multi-center study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa.

    Summary
    EudraCT number
    2012-005716-26
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    31 Jan 2014

    Results information
    Results version number
    v1
    This version publication date
    10 Mar 2016
    First version publication date
    01 Aug 2015
    Other versions
    v2 , v3

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    110021
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00866619
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    GlaxoSmithKline Biologicals, Rue de l’Institut 89, Rixensart, B-1330, Belgium, Rixensart, Belgium, B-1330
    Public contact
    Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Jul 2014
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Jan 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    -To evaluate the protective efficacy of RTS,S/AS01E against clinical malaria disease caused by Plasmodium falciparum in African children whose age at first dose will be from 6-12 weeks and will receive vaccine in co-administration with DTPwHepB/Hib antigens (Tritanrix HepB/Hib) and OPV. Duration of follow up will be for a minimum of 12 months and a maximum of 18 months after completion of the primary course (Primary Analysis). -To evaluate the protective efficacy of RTS,S/AS01E against clinical malaria disease caused by Plasmodium falciparum in African children whose age at first dose will be from 5-17 months. Duration of follow up will be for a minimum of 12 months and a maximum of 18 months after completion of the primary course (Primary Analysis).
    Protection of trial subjects
    The vaccinees were observed closely for at least 30 minutes following the administration of all vaccines used in the study, with appropriate medical treatment readily available in case of an anaphylactic reaction. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Children and infants who received an incomplete primary vaccination schedule (not the 3 doses within the expected timings) did not receive the booster dose of RTS,S/AS01E or control vaccine.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    27 Mar 2009
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    12 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Ghana: 2621
    Country: Number of subjects enrolled
    Tanzania, United Republic of: 3210
    Country: Number of subjects enrolled
    Mozambique: 1637
    Country: Number of subjects enrolled
    Malawi: 1626
    Country: Number of subjects enrolled
    Gabon: 930
    Country: Number of subjects enrolled
    Kenya: 4154
    Country: Number of subjects enrolled
    Burkina Faso: 1281
    Worldwide total number of subjects
    15459
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    15459
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study included 3 phases, a primary (PRI) phase (months [M] 0-3) and a booster (BST) phase at M20, each followed by a related PRI/BST efficacy, immunogenicity and safety (EIS) follow-up (FU) phase, and an EIS extension, from M32 to the median M48 time point for 5-17M subjects & the median M38 time point for 6-12W subjects.

    Pre-assignment
    Screening details
    Screening included the following: check for inclusion/exclusion criteria, vaccination contraindications/precautions & subjects’ medical history, & signing informed consent forms.

    Pre-assignment period milestones
    Number of subjects started
    15459
    Number of subjects completed
    15459

    Period 1
    Period 1 title
    Entire Study Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    R3R (5-17M) Group
    Arm description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine administered at Month 20. The RTS,S/AS01 vaccine was administered intramuscularly in the left deltoid.
    Arm type
    Experimental

    Investigational medicinal product name
    Candidate Plasmodium falciparum malaria vaccine
    Investigational medicinal product code
    RTS,S+AS01E
    Other name
    RTS,S, GSK 257049, RTS,S/AS01
    Pharmaceutical forms
    Powder and suspension for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2 followed by a booster dose at Month 20.

    Arm title
    R3C (5-17M) Group
    Arm description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of Menjugate (or MenC vaccine) administered at Month 20. The RTS,S/AS01 and MenC vaccines were administered intramuscularly in the left deltoid.
    Arm type
    Experimental

    Investigational medicinal product name
    Candidate Plasmodium falciparum malaria vaccine
    Investigational medicinal product code
    RTS,S+AS01E
    Other name
    RTS,S, GSK 257049, RTS,S/AS01
    Pharmaceutical forms
    Powder and suspension for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2

    Investigational medicinal product name
    MENJUGATE KIT
    Investigational medicinal product code
    Other name
    Menjugate, MenC
    Pharmaceutical forms
    Powder and solvent for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose at Month 20

    Arm title
    C3C (5-17M) Group
    Arm description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of Verorab (also referred to as Rabies vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the Menjugate vaccine (MenC) administered at Month 20. The Rabies and MenC vaccines were administered intramuscularly in the left deltoid.
    Arm type
    Active comparator

    Investigational medicinal product name
    Verorab
    Investigational medicinal product code
    Other name
    Rabies
    Pharmaceutical forms
    Powder and suspension for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3-dose primary vaccination course according to a Month 0, 1 and 2

    Investigational medicinal product name
    MENJUGATE KIT
    Investigational medicinal product code
    Other name
    Menjugate, MenC
    Pharmaceutical forms
    Powder and solvent for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose at Month 20

    Arm title
    R3R (6-12W) Group
    Arm description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine co-administered with OPV at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh and the booster dose into the left deltoid; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.
    Arm type
    Experimental

    Investigational medicinal product name
    Candidate Plasmodium falciparum malaria vaccine
    Investigational medicinal product code
    RTS,S+AS01E
    Other name
    RTS,S, GSK 257049, RTS,S/AS01
    Pharmaceutical forms
    Powder and suspension for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2 followed by a booster dose at Month 20.

    Investigational medicinal product name
    Tritanrix-HepB
    Investigational medicinal product code
    DTPw-HBV
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 doses in the anterolateral right thigh according to a Month 0, 1 and 2 of Tritanrix-HepB (DTPw-HBV /Hib) reconstituted into Tritanrix HepB/Hib by combining with Hiberix (Hib) vaccine

    Investigational medicinal product name
    Hiberix
    Investigational medicinal product code
    Hib
    Other name
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 doses in the anterolateral right thigh according to a Month 0, 1 and 2 as part of 3 dose of Tritanrix-HepB (DTPw-HBV /Hib) reconstituted into Tritanrix HepB/Hib by combining with Hiberix (Hib) vaccine

    Investigational medicinal product name
    Polio Sabin (Oral)
    Investigational medicinal product code
    OPV
    Other name
    Pharmaceutical forms
    Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2 followed by a booster dose at Month 20.

    Arm title
    R3C (6-12W) Group
    Arm description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of Menjugate (or MenC vaccine) co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.
    Arm type
    Experimental

    Investigational medicinal product name
    Candidate Plasmodium falciparum malaria vaccine
    Investigational medicinal product code
    RTS,S+AS01E
    Other name
    RTS,S, GSK 257049, RTS,S/AS01
    Pharmaceutical forms
    Powder and suspension for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2

    Investigational medicinal product name
    MENJUGATE KIT
    Investigational medicinal product code
    Other name
    Menjugate, MenC
    Pharmaceutical forms
    Powder and solvent for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose at Month 20

    Investigational medicinal product name
    Tritanrix-HepB
    Investigational medicinal product code
    DTPw-HBV
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 doses in the anterolateral right thigh according to a Month 0, 1 and 2 of Tritanrix-HepB (DTPw-HBV /Hib) reconstituted into Tritanrix HepB/Hib by combining with Hiberix (Hib) vaccine

    Investigational medicinal product name
    Hiberix
    Investigational medicinal product code
    Hib
    Other name
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 doses in the anterolateral right thigh according to a Month 0, 1 and 2 as part of 3 dose of Tritanrix-HepB (DTPw-HBV /Hib) reconstituted into Tritanrix HepB/Hib by combining with Hiberix (Hib) vaccine

    Investigational medicinal product name
    Polio Sabin (Oral)
    Investigational medicinal product code
    OPV
    Other name
    Pharmaceutical forms
    Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2 followed by a booster dose at Month 20.

    Arm title
    C3C (6-12W) Group
    Arm description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of Menjugate (or MenC vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of MenC vaccine co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.
    Arm type
    Active comparator

    Investigational medicinal product name
    MENJUGATE KIT
    Investigational medicinal product code
    Other name
    Menjugate, MenC
    Pharmaceutical forms
    Powder and solvent for suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2 followed by a booster dose at Month 20.

    Investigational medicinal product name
    Tritanrix-HepB
    Investigational medicinal product code
    DTPw-HBV
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 doses in the anterolateral right thigh according to a Month 0, 1 and 2 of Tritanrix-HepB (DTPw-HBV /Hib) reconstituted into Tritanrix HepB/Hib by combining with Hiberix (Hib) vaccine

    Investigational medicinal product name
    Hiberix
    Investigational medicinal product code
    Hib
    Other name
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    3 doses in the anterolateral right thigh according to a Month 0, 1 and 2 as part of 3 dose of Tritanrix-HepB (DTPw-HBV /Hib) reconstituted into Tritanrix HepB/Hib by combining with Hiberix (Hib) vaccine

    Investigational medicinal product name
    Polio Sabin (Oral)
    Investigational medicinal product code
    OPV
    Other name
    Pharmaceutical forms
    Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    3 primary doses according to a Month 0, 1 and 2 followed by a booster dose at Month 20.

    Number of subjects in period 1
    R3R (5-17M) Group R3C (5-17M) Group C3C (5-17M) Group R3R (6-12W) Group R3C (6-12W) Group C3C (6-12W) Group
    Started
    2976
    2972
    2974
    2180
    2178
    2179
    Completed
    2064
    2038
    2085
    1555
    1533
    1549
    Not completed
    912
    934
    889
    625
    645
    630
         Consent withdrawn by subject
    297
    290
    272
    157
    138
    144
         Adverse event, non-fatal
    61
    51
    47
    51
    55
    44
         Lost to follow-up
    552
    593
    568
    395
    435
    425
         Protocol deviation
    2
    -
    2
    22
    17
    17

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    R3R (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine administered at Month 20. The RTS,S/AS01 vaccine was administered intramuscularly in the left deltoid.

    Reporting group title
    R3C (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of Menjugate (or MenC vaccine) administered at Month 20. The RTS,S/AS01 and MenC vaccines were administered intramuscularly in the left deltoid.

    Reporting group title
    C3C (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of Verorab (also referred to as Rabies vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the Menjugate vaccine (MenC) administered at Month 20. The Rabies and MenC vaccines were administered intramuscularly in the left deltoid.

    Reporting group title
    R3R (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine co-administered with OPV at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh and the booster dose into the left deltoid; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    R3C (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of Menjugate (or MenC vaccine) co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    C3C (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of Menjugate (or MenC vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of MenC vaccine co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group values
    R3R (5-17M) Group R3C (5-17M) Group C3C (5-17M) Group R3R (6-12W) Group R3C (6-12W) Group C3C (6-12W) Group Total
    Number of subjects
    2976 2972 2974 2180 2178 2179 15459
    Age categorical
    Units: Subjects
        Infants and toddlers (28 days-23 months)
    2976 2972 2974 2180 2178 2179 15459
    Age continuous
    Units: months
        arithmetic mean (standard deviation)
    10.7 ( 3.79 ) 10.6 ( 3.82 ) 10.6 ( 3.75 ) 7.2 ( 1.45 ) 7.1 ( 1.39 ) 7.1 ( 1.43 ) -
    Gender categorical
    Units: Subjects
        Female
    1467 1500 1503 1064 1060 1100 7694
        Male
    1509 1472 1471 1116 1118 1079 7765

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    R3R (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine administered at Month 20. The RTS,S/AS01 vaccine was administered intramuscularly in the left deltoid.

    Reporting group title
    R3C (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of Menjugate (or MenC vaccine) administered at Month 20. The RTS,S/AS01 and MenC vaccines were administered intramuscularly in the left deltoid.

    Reporting group title
    C3C (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of Verorab (also referred to as Rabies vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the Menjugate vaccine (MenC) administered at Month 20. The Rabies and MenC vaccines were administered intramuscularly in the left deltoid.

    Reporting group title
    R3R (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine co-administered with OPV at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh and the booster dose into the left deltoid; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    R3C (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of Menjugate (or MenC vaccine) co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    C3C (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of Menjugate (or MenC vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of MenC vaccine co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Subject analysis set title
    RTS,S/AS01 (5-17M)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This group results from the pooling of the R3R (5-17M) and R3C (5-17M) groups and include subjects who received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049) according to a Month 0, 1 and 2 schedule followed by, at Month 20, either a booster dose of the RTS,S/AS01 vaccine or a dose of Menjugate (or MenC). Refer to the respective descriptions for the R3R (5-17M) and R3C (5-17M) groups for details on routes of vaccination.

    Subject analysis set title
    RTS,S/AS01 (6-12W) Group
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This group results from the pooling of the R3R (6-12W) and R3C (6-12W) groups and include subjects who received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049) co-administered with Polio Sabin (or OPV) and Tritanrix HepB/Hib (or DTPwHepB/Hib) according to a Month 0, 1 and 2 schedule followed by, at Month 20, either a booster dose of the RTS,S/AS01 and OPV vaccines or a booster dose of Menjugate (or MenC) and OPV vaccines. Refer to the respective descriptions for the R3R (6-12W) and R3C (6-12W) groups for details on routes of vaccination

    Subject analysis set title
    RTS,S/AS01 Group
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This group results from the pooling of the R3R (5-17M), R3C (5-17M), R3R (6-12W) and R3C (6-12W) groups. Subjects aged 5 to 17 months at first vaccination received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049 vaccine) according to a Month 0, 1 and 2 schedule, followed by, at Month 20, either a booster dose of the RTS,S/AS01 vaccine or a dose of Menjugate (or MenC). Subjects aged 6 to 12 weeks at first vaccination received a 3-dose primary vaccination course of RTS,S/AS01 vaccine co-administered with Polio Sabin (or OPV) and Tritanrix HepB/Hib (or DTPwHepB/Hib) according to a Month 0, 1 and 2 schedule followed by, at Month 20, either a booster dose of RTS,S/AS01 and OPV vaccines or a booster dose of Menjugate (or MenC) and OPV vaccines. Refer to the respective descriptions for the R3R (5-17M), R3C (5-17M), R3R (6-12W) and R3C (6-12W) groups for details on routes of vaccination.

    Subject analysis set title
    R3R Group
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This group results from the pooling of the R3R (5-17M) and R3R (6-12W) groups and include subjects who received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049) according to a Month 0, 1 and 2 schedule, followed by, at Month 20, either a booster dose of the RTS,S/AS01 vaccine. Refer to the respective descriptions for the R3R (5-17M) and R3R (6-12W) groups for details on other vaccines administered depending on age of subjects and routes of vaccination.

    Subject analysis set title
    R3C Group
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This group results from the pooling of the R3C (5-17M) and R3C (6-12W) groups and include subjects who received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049) according to a Month 0, 1 and 2 schedule, followed by, at Month 20, either a booster dose of Menjugate (or MenC). Refer to the respective descriptions for the R3C (5-17M) and R3C (6-12W) groups for details on other vaccines administered depending on age of subjects and routes of vaccination.

    Subject analysis set title
    C3C Group
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    This group results from the pooling of the C3C (5-17M) and C3C (6-12W) groups and include subjects who received a 3-dose primary vaccination course of either Verorab (also referred to as Rabies vaccine (subjects aged 5-17 months at first vaccination) or Menjugate (or MenC) (subjects aged 6-12 weeks at first vaccination according to a Month 0, 1 and 2 schedule, followed by, at Month 20, either a booster dose of the MenC vaccine. Refer to the respective descriptions for the C3C (5-17M) and C3C (6-12W) groups for details on other vaccines administered depending on age of subjects and routes of vaccination.

    Primary: Time to first or only clinical episode of Plasmodium falciparum (P. falciparum) malaria infection (CPFMI), or clinical malaria episode, of Primary Case Definition (CPFMI-PCD) - In subjects enrolled aged 5-17 months

    Close Top of page
    End point title
    Time to first or only clinical episode of Plasmodium falciparum (P. falciparum) malaria infection (CPFMI), or clinical malaria episode, of Primary Case Definition (CPFMI-PCD) - In subjects enrolled aged 5-17 months [1]
    End point description
    A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia > 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is, the number of CPFMI events reported (n) over the period elapsed until the CPFMI event occurred for each group (T in year = sum of follow-up period expressed in years censored at the first occurrence of event in each group). Analysis for this outcome was solely performed on subjects in the 5-17 months age category
    End point type
    Primary
    End point timeframe
    From Month 2.5 to Month 14
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Analysis for this endpoint was done only on subjects in 6-12weeks age category, and, for subjects receiving RTS,S, in a pooled manner, that is, pooling subjects from R3R (6-12W) and R3C (6-12W).
    End point values
    C3C (5-17M) Group RTS,S/AS01 (5-17M)
    Number of subjects analysed
    1466
    2830
    Units: n/T
    number (not applicable)
        RfoCPFMI-PCD 5-17M M2.5-14
    0.833
    0.435
    Statistical analysis title
    Vaccine efficacy (VE) RTS,S/AS01 vs control
    Statistical analysis description
    The analysis aimed to compare RfoCPFMI between groups over the Months 2.5-14 time period. Using RfoCFPMI, a Cox regression model was used to evaluate vaccine efficacy (VE) allowing for adjustment by factors . VE was calculated as 1 minus [Hazard Ratio (HR) in RTS,S/AS01 (5-17M) Group (HR1) divided by HR in control C3C (5-17M) Group (HR2)], i. e. 1 - (HR1/HR2).
    Comparison groups
    C3C (5-17M) Group v RTS,S/AS01 (5-17M)
    Number of subjects included in analysis
    4296
    Analysis specification
    Pre-specified
    Analysis type
    superiority [2]
    P-value
    < 0.0001 [3]
    Method
    Regression, Cox
    Parameter type
    VE (see above)
    Point estimate
    55.8
    Confidence interval
         level
    97.5%
         sides
    2-sided
         lower limit
    50.6
         upper limit
    60.4
    Notes
    [2] - Point estimate of efficacy was adjusted for study site as stratification factor for the analysis. This efficacy was calculated with the first 6000 subjects enrolled in the 5-17 months (5-17M) age category. Results were uncorrected for the double enrolment of one subject receiving the RTS,S/AS01 vaccine in the 5-17Ms age category. Criterion for success = lower limit (LL) of 97.5% confidence interval (CI) of VE > 0.
    [3] - The p-value presented was calculated using the likelihood ratio test.

    Primary: Time to first or only clinical episode of Plasmodium falciparum (P. falciparum) malaria infection (CPFMI), or clinical malaria episode, of Primary Case Definition (CPFMI-PCD) – In subjects enrolled aged 6-12 weeks

    Close Top of page
    End point title
    Time to first or only clinical episode of Plasmodium falciparum (P. falciparum) malaria infection (CPFMI), or clinical malaria episode, of Primary Case Definition (CPFMI-PCD) – In subjects enrolled aged 6-12 weeks [4]
    End point description
    A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia > 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is, the number of CPFMI events reported (n) over the period elapsed until the CPFMI event occurred for each group (T in year = sum of follow-up period expressed in years censored at the first occurrence of event in each group). Analysis for this outcome was solely performed on subjects in the 6-12 weeks (6-12W) age category
    End point type
    Primary
    End point timeframe
    From Month 2.5 to Month 14
    Notes
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Analysis for this endpoint was done only on subjects in 5-17 months age category, and, for subjects receiving RTS,S, in a pooled manner, that is, pooling subjects from R3R (5-17M) and R3C (5-17M).
    End point values
    C3C (6-12W) Group RTS,S/AS01 (6-12W) Group
    Number of subjects analysed
    2008
    3995
    Units: n/T
    number (not applicable)
        RfoCPFMI-PCD 6-12W M2.5-14
    0.484
    0.367
    Statistical analysis title
    Vaccine efficacy (VE) RTS,S/AS01 vs control
    Statistical analysis description
    The analysis aimed to compare RfoCPFMI between groups over the Months 2.5-14 time period. Using RfoCFPMI, a Cox regression model was used to evaluate vaccine efficacy (VE) allowing for adjustment by factors . VE was calculated as 1 minus [Hazard Ratio (HR) in RTS,S/AS01 (5-17M) Group (HR1) divided by HR in control C3C (5-17M) Group (HR2)], i. e. 1 - (HR1/HR2).
    Comparison groups
    C3C (6-12W) Group v RTS,S/AS01 (6-12W) Group
    Number of subjects included in analysis
    6003
    Analysis specification
    Pre-specified
    Analysis type
    superiority [5]
    P-value
    < 0.0001 [6]
    Method
    Regression, Cox
    Parameter type
    VE (see above)
    Point estimate
    31.315
    Confidence interval
         level
    97.5%
         sides
    2-sided
         lower limit
    23.556
         upper limit
    38.286
    Notes
    [5] - Point estimate of efficacy was adjusted for study site as stratification factor for the analysis. Criterion for success = lower limit (LL) of 97.5% confidence interval (CI) of VE > 0.
    [6] - The p-value presented was calculated using the likelihood ratio test.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited and unsolicited AEs: respectively 7-day (D) (D0-6) & 30-D (D0-29) follow-up (FU) periods post vaccination (PRI or BST); SAEs: Month [M] 0 to study end (median FU = 48M in 5-17M subjects & 38M for 6-12W subjects).
    Adverse event reporting additional description
    In this section, RTS,S/AS01 (5-17M) & RTS,S/AS01 (6-12W) groups are only applicable for solicited & unsolicited AEs post PRI vaccination, with all not applicable other Ns coded as ‘1’ and ns coded as ‘0’. Occurrence of reported AEs (all/related) was not available & is encoded as equal to number of subjects affected.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    17.0
    Reporting groups
    Reporting group title
    R3R (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine administered at Month 20. The RTS,S/AS01 vaccine was administered intramuscularly in the left deltoid.

    Reporting group title
    R3C (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) according to a Month 0, 1 and 2 followed by a booster dose of Menjugate (or MenC vaccine) administered at Month 20. The RTS,S/AS01 and MenC vaccines were administered intramuscularly in the left deltoid.

    Reporting group title
    C3C (5-17M) Group
    Reporting group description
    Subjects in this group, aged 5 to 17 months at first vaccination, received a 3-dose primary vaccination course of Verorab (also referred to as Rabies vaccine) according to a Month 0, 1 and 2 followed by a booster dose of the Menjugate vaccine (MenC) administered at Month 20. The Rabies and MenC vaccines were administered intramuscularly in the left deltoid.

    Reporting group title
    R3R (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of the same RTS,S/AS01 vaccine co-administered with OPV at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh and the booster dose into the left deltoid; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    R3C (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049, vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of Menjugate (or MenC vaccine) co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the primary RTS,S/AS01 vaccine doses were injected in the anterolateral left thigh; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    C3C (6-12W) Group
    Reporting group description
    Subjects in this group, aged 6 to 12 weeks at first vaccination, received a 3-dose primary vaccination course of Menjugate (or MenC vaccine) co-administered with Polio Sabin (or OPV vaccine) and Tritanrix HepB/Hib (or DTPwHepB/Hib vaccine) (reconstituted from Tritanrix HepB and Hiberix vaccines) according to a Month 0, 1 and 2 followed by a booster dose of dose of MenC vaccine co-administered with OPV vaccine at Month 20. All vaccines were administered intramuscularly, except the OPV vaccine given orally; the MenC vaccine was injected in the left thigh for children < 1 year of age and into the left deltoid in children > 1 year of age; the DTPwHepB/Hib vaccine was injected in the anterolateral right thigh.

    Reporting group title
    RTS,S/AS01 (5-17M) Group
    Reporting group description
    This group results from the pooling of the R3R (5-17M) and R3C (5-17M) groups and include subjects who received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049) according to a Month 0, 1 and 2 schedule followed by, at Month 20, either a booster dose of the RTS,S/AS01 vaccine or a dose of Menjugate (or MenC). Refer to the respective descriptions for the R3R (5-17M) and R3C (5-17M) groups for details on routes of vaccination.

    Reporting group title
    RTS,S/AS01 (6-12W) Group
    Reporting group description
    This group results from the pooling of the R3R (6-12W) and R3C (6-12W) groups and include subjects who received a 3-dose primary vaccination course of the RTS,S/AS01 vaccine (also referred to as RTS,S or GSK 257049) co-administered with Polio Sabin (or OPV) and Tritanrix HepB/Hib (or DTPwHepB/Hib) according to a Month 0, 1 and 2 schedule followed by, at Month 20, either a booster dose of the RTS,S/AS01 and OPV vaccines or a booster dose of Menjugate (or MenC) and OPV vaccines. Refer to the respective descriptions for the R3R (6-12W) and R3C (6-12W) groups for details on routes of vaccination.

    Serious adverse events
    R3R (5-17M) Group R3C (5-17M) Group C3C (5-17M) Group R3R (6-12W) Group R3C (6-12W) Group C3C (6-12W) Group RTS,S/AS01 (5-17M) Group RTS,S/AS01 (6-12W) Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    720 / 2976 (24.19%)
    752 / 2972 (25.30%)
    846 / 2974 (28.45%)
    580 / 2180 (26.61%)
    602 / 2178 (27.64%)
    619 / 2179 (28.41%)
    0 / 1479 (0.00%)
    0 / 1462 (0.00%)
         number of deaths (all causes)
    61
    51
    46
    51
    55
    42
    0
    0
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acute promyelocytic leukaemia
         subjects affected / exposed [1]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain neoplasm
         subjects affected / exposed [2]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inflammatory pseudotumour
         subjects affected / exposed [3]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Langerhans’ cell histiocytosis
         subjects affected / exposed [4]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Haematoma
         subjects affected / exposed [5]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypovolaemic shock
         subjects affected / exposed [6]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Shock
         subjects affected / exposed [7]
    0 / 2976 (0.00%)
    3 / 2972 (0.10%)
    5 / 2974 (0.17%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    4 / 2179 (0.18%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 5
    0 / 1
    0 / 2
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Death
         subjects affected / exposed [8]
    3 / 2976 (0.10%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    2 / 2180 (0.09%)
    1 / 2178 (0.05%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
    0 / 2
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
    0 / 2
    0 / 1
    0 / 3
    0 / 0
    0 / 0
    Drowning
         subjects affected / exposed [9]
    3 / 2976 (0.10%)
    2 / 2972 (0.07%)
    3 / 2974 (0.10%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 3
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 3
    0 / 2
    0 / 3
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Generalised oedema
         subjects affected / exposed [10]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hernia
         subjects affected / exposed [11]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypothermia
         subjects affected / exposed [12]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injection site reaction
         subjects affected / exposed [13]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed [14]
    18 / 2976 (0.60%)
    10 / 2972 (0.34%)
    16 / 2974 (0.54%)
    15 / 2180 (0.69%)
    11 / 2178 (0.51%)
    18 / 2179 (0.83%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    1 / 18
    2 / 10
    0 / 16
    2 / 15
    0 / 11
    2 / 18
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 3
    0 / 0
    0 / 3
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    Immune system disorders
    Allergy to arthropod sting
         subjects affected / exposed [15]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaphylactic reaction
         subjects affected / exposed [16]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypersensitivity
         subjects affected / exposed [17]
    0 / 2976 (0.00%)
    3 / 2972 (0.10%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Social circumstances
    Child abuse
         subjects affected / exposed [18]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sexual abuse
         subjects affected / exposed [19]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Acquired phimosis
         subjects affected / exposed [20]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Apnoeic attack
         subjects affected / exposed [21]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asphyxia
         subjects affected / exposed [22]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aspiration
         subjects affected / exposed [23]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed [24]
    9 / 2976 (0.30%)
    6 / 2972 (0.20%)
    8 / 2974 (0.27%)
    6 / 2180 (0.28%)
    3 / 2178 (0.14%)
    7 / 2179 (0.32%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 9
    0 / 6
    0 / 8
    0 / 6
    0 / 3
    0 / 7
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchial hyperreactivity
         subjects affected / exposed [25]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchospasm
         subjects affected / exposed [26]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    3 / 2974 (0.10%)
    3 / 2180 (0.14%)
    5 / 2178 (0.23%)
    5 / 2179 (0.23%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 3
    0 / 3
    0 / 5
    0 / 5
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cough
         subjects affected / exposed [27]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed [28]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed [29]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstructive airways disorder
         subjects affected / exposed [30]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed [31]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed [32]
    7 / 2976 (0.24%)
    1 / 2972 (0.03%)
    6 / 2974 (0.20%)
    2 / 2180 (0.09%)
    2 / 2178 (0.09%)
    4 / 2179 (0.18%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 1
    0 / 6
    0 / 2
    0 / 2
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 1
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed [33]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed [34]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory acidosis
         subjects affected / exposed [35]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory arrest
         subjects affected / exposed [36]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory disorder
         subjects affected / exposed [37]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Neurodevelopmental disorder
         subjects affected / exposed [38]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Accidental exposure to product
         subjects affected / exposed [39]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Accidental poisoning
         subjects affected / exposed [40]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Animal bite
         subjects affected / exposed [41]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthropod sting
         subjects affected / exposed [42]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchitis chemical
         subjects affected / exposed [43]
    3 / 2976 (0.10%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Burns first degree
         subjects affected / exposed [44]
    2 / 2976 (0.07%)
    2 / 2972 (0.07%)
    1 / 2974 (0.03%)
    2 / 2180 (0.09%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 1
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Burns second degree
         subjects affected / exposed [45]
    1 / 2976 (0.03%)
    5 / 2972 (0.17%)
    2 / 2974 (0.07%)
    3 / 2180 (0.14%)
    2 / 2178 (0.09%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 5
    0 / 2
    0 / 3
    0 / 2
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chemical injury
         subjects affected / exposed [46]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chemical poisoning
         subjects affected / exposed [47]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    7 / 2974 (0.24%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 7
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clavicle fracture
         subjects affected / exposed [48]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Crush injury
         subjects affected / exposed [49]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disinfectant poisoning
         subjects affected / exposed [50]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Exposure to toxic agent
         subjects affected / exposed [51]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye contusion
         subjects affected / exposed [52]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye injury
         subjects affected / exposed [53]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed [54]
    3 / 2976 (0.10%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    2 / 2180 (0.09%)
    2 / 2178 (0.09%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 1
    0 / 2
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foreign body
         subjects affected / exposed [55]
    4 / 2976 (0.13%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foreign body aspiration
         subjects affected / exposed [56]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fractured skull depressed
         subjects affected / exposed [57]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Greenstick fracture
         subjects affected / exposed [58]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed [59]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    4 / 2178 (0.18%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 4
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    Herbal toxicity
         subjects affected / exposed [60]
    2 / 2976 (0.07%)
    3 / 2972 (0.10%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    2 / 2178 (0.09%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 2
    0 / 0
    0 / 2
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 3
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Human bite
         subjects affected / exposed [61]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Humerus fracture
         subjects affected / exposed [62]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Joint injury
         subjects affected / exposed [63]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Laceration
         subjects affected / exposed [64]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Limb injury
         subjects affected / exposed [65]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Limb traumatic amputation
         subjects affected / exposed [66]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Penis injury
         subjects affected / exposed [67]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Petroleum distillate poisoning
         subjects affected / exposed [68]
    2 / 2976 (0.07%)
    2 / 2972 (0.07%)
    4 / 2974 (0.13%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 4
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis chemical
         subjects affected / exposed [69]
    4 / 2976 (0.13%)
    1 / 2972 (0.03%)
    4 / 2974 (0.13%)
    2 / 2180 (0.09%)
    2 / 2178 (0.09%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 4
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Poisoning
         subjects affected / exposed [70]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary contusion
         subjects affected / exposed [71]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed [72]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sciatic nerve injury
         subjects affected / exposed [73]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin injury
         subjects affected / exposed [74]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Snake bite
         subjects affected / exposed [75]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Soft tissue injury
         subjects affected / exposed [76]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thermal burn
         subjects affected / exposed [77]
    15 / 2976 (0.50%)
    10 / 2972 (0.34%)
    15 / 2974 (0.50%)
    14 / 2180 (0.64%)
    9 / 2178 (0.41%)
    11 / 2179 (0.50%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 15
    0 / 10
    0 / 15
    0 / 14
    0 / 9
    0 / 11
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Tibia fracture
         subjects affected / exposed [78]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vaccination failure
         subjects affected / exposed [79]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound
         subjects affected / exposed [80]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wrist fracture
         subjects affected / exposed [81]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    Atrial septal defect
         subjects affected / exposed [82]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral palsy
         subjects affected / exposed [83]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Choledochal cyst
         subjects affected / exposed [84]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Congenital megacolon
         subjects affected / exposed [85]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Cryptorchism
         subjects affected / exposed [86]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fallot’s tetralogy
         subjects affected / exposed [87]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Glucose-6-phosphate dehydrogenase deficiency
         subjects affected / exposed [88]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydrocele
         subjects affected / exposed [89]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Phimosis
         subjects affected / exposed [90]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sickle cell anaemia
         subjects affected / exposed [91]
    1 / 2976 (0.03%)
    4 / 2972 (0.13%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    3 / 2178 (0.14%)
    5 / 2179 (0.23%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 1
    0 / 1
    0 / 3
    0 / 5
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Sickle cell anaemia with crisis
         subjects affected / exposed [92]
    4 / 2976 (0.13%)
    4 / 2972 (0.13%)
    6 / 2974 (0.20%)
    1 / 2180 (0.05%)
    4 / 2178 (0.18%)
    5 / 2179 (0.23%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 4
    0 / 6
    0 / 1
    0 / 4
    0 / 5
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Trisomy 21
         subjects affected / exposed [93]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urethral valves
         subjects affected / exposed [94]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ventricular septal defect
         subjects affected / exposed [95]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac arrest
         subjects affected / exposed [96]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed [97]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiomyopathy
         subjects affected / exposed [98]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed [99]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Arachnoid cyst
         subjects affected / exposed [100]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebellar ataxia
         subjects affected / exposed [101]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral atrophy
         subjects affected / exposed [102]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Convulsion
         subjects affected / exposed [103]
    57 / 2976 (1.92%)
    45 / 2972 (1.51%)
    58 / 2974 (1.95%)
    45 / 2180 (2.06%)
    32 / 2178 (1.47%)
    32 / 2179 (1.47%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 57
    0 / 45
    0 / 58
    0 / 45
    0 / 32
    0 / 32
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 8
    0 / 8
    0 / 10
    0 / 4
    0 / 4
    0 / 4
    0 / 0
    0 / 0
    Depressed level of consciousness
         subjects affected / exposed [104]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalomalacia
         subjects affected / exposed [105]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed [106]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epilepsy
         subjects affected / exposed [107]
    3 / 2976 (0.10%)
    10 / 2972 (0.34%)
    2 / 2974 (0.07%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 10
    0 / 2
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile convulsion
         subjects affected / exposed [108]
    159 / 2976 (5.34%)
    184 / 2972 (6.19%)
    164 / 2974 (5.51%)
    100 / 2180 (4.59%)
    90 / 2178 (4.13%)
    101 / 2179 (4.64%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    6 / 159
    1 / 184
    1 / 164
    3 / 100
    1 / 90
    0 / 101
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 4
    0 / 1
    0 / 3
    0 / 2
    0 / 3
    0 / 3
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed [109]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed [110]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hemiplegia
         subjects affected / exposed [111]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydrocephalus
         subjects affected / exposed [112]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Loss of consciousness
         subjects affected / exposed [113]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Meningism
         subjects affected / exposed [114]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mental retardation
         subjects affected / exposed [115]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolic encephalopathy
         subjects affected / exposed [116]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Monoparesis
         subjects affected / exposed [117]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myoclonus
         subjects affected / exposed [118]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paraparesis
         subjects affected / exposed [119]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Speech disorder developmental
         subjects affected / exposed [120]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Uraemic encephalopathy
         subjects affected / exposed [121]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed [122]
    126 / 2976 (4.23%)
    150 / 2972 (5.05%)
    197 / 2974 (6.62%)
    90 / 2180 (4.13%)
    106 / 2178 (4.87%)
    116 / 2179 (5.32%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 126
    0 / 150
    0 / 197
    0 / 90
    0 / 106
    0 / 116
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 10
    0 / 7
    0 / 12
    0 / 3
    0 / 14
    0 / 4
    0 / 0
    0 / 0
    Dislocation of vertebra
         subjects affected / exposed [123]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disseminated intravascular coagulation
         subjects affected / exposed [124]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemolysis
         subjects affected / exposed [125]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemolytic anaemia
         subjects affected / exposed [126]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Hypochromic anaemia
         subjects affected / exposed [127]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intravascular haemolysis
         subjects affected / exposed [128]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukaemoid reaction
         subjects affected / exposed [129]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphadenitis
         subjects affected / exposed [130]
    4 / 2976 (0.13%)
    3 / 2972 (0.10%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 3
    0 / 1
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed [131]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed [132]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed [133]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Deafness
         subjects affected / exposed [134]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hearing impaired
         subjects affected / exposed [135]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Periorbital oedema
         subjects affected / exposed [136]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Aphthous stomatitis
         subjects affected / exposed [137]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed [138]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed [139]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enteritis
         subjects affected / exposed [140]
    10 / 2976 (0.34%)
    18 / 2972 (0.61%)
    15 / 2974 (0.50%)
    7 / 2180 (0.32%)
    10 / 2178 (0.46%)
    18 / 2179 (0.83%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 10
    0 / 18
    0 / 15
    0 / 7
    0 / 10
    0 / 18
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 3
    0 / 0
    0 / 0
    Food poisoning
         subjects affected / exposed [141]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed [142]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    2 / 2974 (0.07%)
    2 / 2180 (0.09%)
    1 / 2178 (0.05%)
    4 / 2179 (0.18%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 2
    0 / 2
    0 / 1
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed [143]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal motility disorder
         subjects affected / exposed [144]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed [145]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematemesis
         subjects affected / exposed [146]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ileus paralytic
         subjects affected / exposed [147]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed [148]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed [149]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    2 / 2180 (0.09%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal perforation
         subjects affected / exposed [150]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intussusception
         subjects affected / exposed [151]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mouth ulceration
         subjects affected / exposed [152]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal polyp
         subjects affected / exposed [153]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal prolapse
         subjects affected / exposed [154]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stomatitis
         subjects affected / exposed [155]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    2 / 2180 (0.09%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stress ulcer
         subjects affected / exposed [156]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Umbilical hernia
         subjects affected / exposed [157]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Umbilical hernia, obstructive
         subjects affected / exposed [158]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed [159]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed [160]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed [161]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Drug hypersensitivity
         subjects affected / exposed [162]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis
         subjects affected / exposed [163]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis acute
         subjects affected / exposed [164]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis toxic
         subjects affected / exposed [165]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune reconstitution inflammatory syndrome
         subjects affected / exposed [166]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Dermatitis
         subjects affected / exposed [167]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dermatitis allergic
         subjects affected / exposed [168]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dermatitis exfoliative
         subjects affected / exposed [169]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Drug eruption
         subjects affected / exposed [170]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erythema multiforme
         subjects affected / exposed [171]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed [172]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash maculo-papular
         subjects affected / exposed [173]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash papular
         subjects affected / exposed [174]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin lesion
         subjects affected / exposed [175]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stevens-Johnson syndrome
         subjects affected / exposed [176]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urticaria
         subjects affected / exposed [177]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vitiligo
         subjects affected / exposed [178]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Glomerulonephritis
         subjects affected / exposed [179]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Glomerulonephritis acute
         subjects affected / exposed [180]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed [181]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nephritis
         subjects affected / exposed [182]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nephrotic syndrome
         subjects affected / exposed [183]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure acute
         subjects affected / exposed [184]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal tubular necrosis
         subjects affected / exposed [185]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed [186]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthritis
         subjects affected / exposed [187]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Compartment syndrome
         subjects affected / exposed [188]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dactylitis
         subjects affected / exposed [189]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    2 / 2180 (0.09%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Joint effusion
         subjects affected / exposed [190]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myositis
         subjects affected / exposed [191]
    2 / 2976 (0.07%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed [192]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rickets
         subjects affected / exposed [193]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Torticollis
         subjects affected / exposed [194]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Abscess
         subjects affected / exposed [195]
    7 / 2976 (0.24%)
    7 / 2972 (0.24%)
    5 / 2974 (0.17%)
    4 / 2180 (0.18%)
    8 / 2178 (0.37%)
    5 / 2179 (0.23%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 7
    0 / 5
    0 / 4
    0 / 8
    0 / 5
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abscess jaw
         subjects affected / exposed [196]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abscess limb
         subjects affected / exposed [197]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    3 / 2974 (0.10%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 3
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abscess neck
         subjects affected / exposed [198]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acarodermatitis
         subjects affected / exposed [199]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    AIDS dementia complex
         subjects affected / exposed [200]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Amoebiasis
         subjects affected / exposed [201]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthritis bacterial
         subjects affected / exposed [202]
    2 / 2976 (0.07%)
    7 / 2972 (0.24%)
    1 / 2974 (0.03%)
    3 / 2180 (0.14%)
    3 / 2178 (0.14%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 7
    0 / 1
    0 / 3
    0 / 3
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ascariasis
         subjects affected / exposed [203]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atypical pneumonia
         subjects affected / exposed [204]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed [205]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial infection
         subjects affected / exposed [206]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bone tuberculosis
         subjects affected / exposed [207]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain abscess
         subjects affected / exposed [208]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Breast abscess
         subjects affected / exposed [209]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchiolitis
         subjects affected / exposed [210]
    25 / 2976 (0.84%)
    13 / 2972 (0.44%)
    18 / 2974 (0.61%)
    19 / 2180 (0.87%)
    13 / 2178 (0.60%)
    24 / 2179 (1.10%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 25
    0 / 13
    0 / 18
    0 / 19
    0 / 13
    0 / 24
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed [211]
    13 / 2976 (0.44%)
    15 / 2972 (0.50%)
    21 / 2974 (0.71%)
    6 / 2180 (0.28%)
    11 / 2178 (0.51%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 13
    0 / 15
    0 / 21
    0 / 6
    0 / 11
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Bronchopneumonia
         subjects affected / exposed [212]
    33 / 2976 (1.11%)
    35 / 2972 (1.18%)
    40 / 2974 (1.34%)
    35 / 2180 (1.61%)
    19 / 2178 (0.87%)
    34 / 2179 (1.56%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 33
    0 / 35
    0 / 40
    0 / 35
    0 / 19
    0 / 34
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 3
    0 / 1
    0 / 1
    0 / 4
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    Bullous impetigo
         subjects affected / exposed [213]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Burkholderia cepacia complex sepsis
         subjects affected / exposed [214]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Burn infection
         subjects affected / exposed [215]
    1 / 2976 (0.03%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Candida infection
         subjects affected / exposed [216]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed [217]
    8 / 2976 (0.27%)
    7 / 2972 (0.24%)
    6 / 2974 (0.20%)
    6 / 2180 (0.28%)
    4 / 2178 (0.18%)
    6 / 2179 (0.28%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 8
    0 / 7
    0 / 6
    0 / 6
    0 / 4
    0 / 6
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis of male external genital organ
         subjects affected / exposed [218]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis orbital
         subjects affected / exposed [219]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis pharyngeal
         subjects affected / exposed [220]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Central nervous system viral infection
         subjects affected / exposed [221]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral malaria
         subjects affected / exposed [222]
    4 / 2976 (0.13%)
    4 / 2972 (0.13%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 4
    0 / 0
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 3
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Cholera
         subjects affected / exposed [223]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Conjunctivitis
         subjects affected / exposed [224]
    2 / 2976 (0.07%)
    4 / 2972 (0.13%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 4
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Conjunctivitis bacterial
         subjects affected / exposed [225]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Croup infectious
         subjects affected / exposed [226]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dermatitis infected
         subjects affected / exposed [227]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disseminated tuberculosis
         subjects affected / exposed [228]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysentery
         subjects affected / exposed [229]
    11 / 2976 (0.37%)
    13 / 2972 (0.44%)
    9 / 2974 (0.30%)
    4 / 2180 (0.18%)
    6 / 2178 (0.28%)
    7 / 2179 (0.32%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 11
    0 / 13
    0 / 9
    0 / 4
    0 / 6
    0 / 7
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Eczema infected
         subjects affected / exposed [230]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Empyema
         subjects affected / exposed [231]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalitis
         subjects affected / exposed [232]
    4 / 2976 (0.13%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 2
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Encephalitis viral
         subjects affected / exposed [233]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Encephalomyelitis
         subjects affected / exposed [234]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterococcal sepsis
         subjects affected / exposed [235]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed [236]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia sepsis
         subjects affected / exposed [237]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia urinary tract infection
         subjects affected / exposed [238]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
    0 / 1
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Exanthema subitum
         subjects affected / exposed [239]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile infection
         subjects affected / exposed [240]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Furuncle
         subjects affected / exposed [241]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed [242]
    153 / 2976 (5.14%)
    148 / 2972 (4.98%)
    177 / 2974 (5.95%)
    162 / 2180 (7.43%)
    171 / 2178 (7.85%)
    171 / 2179 (7.85%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 153
    0 / 148
    0 / 177
    0 / 162
    0 / 171
    0 / 171
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 14
    0 / 7
    0 / 8
    0 / 14
    0 / 11
    0 / 10
    0 / 0
    0 / 0
    Gastroenteritis Escherichia coli
         subjects affected / exposed [243]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis salmonella
         subjects affected / exposed [244]
    2 / 2976 (0.07%)
    3 / 2972 (0.10%)
    0 / 2974 (0.00%)
    5 / 2180 (0.23%)
    2 / 2178 (0.09%)
    4 / 2179 (0.18%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 0
    0 / 5
    0 / 2
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis shigella
         subjects affected / exposed [245]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis viral
         subjects affected / exposed [246]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal candidiasis
         subjects affected / exposed [247]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Giardiasis
         subjects affected / exposed [248]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gingivitis
         subjects affected / exposed [249]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Groin abscess
         subjects affected / exposed [250]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemophilus sepsis
         subjects affected / exposed [251]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Helminthic infection
         subjects affected / exposed [252]
    2 / 2976 (0.07%)
    8 / 2972 (0.27%)
    6 / 2974 (0.20%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 8
    0 / 6
    0 / 1
    0 / 2
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis A
         subjects affected / exposed [253]
    2 / 2976 (0.07%)
    2 / 2972 (0.07%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis B
         subjects affected / exposed [254]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis infectious
         subjects affected / exposed [255]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HIV associated nephropathy
         subjects affected / exposed [256]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    HIV infection
         subjects affected / exposed [257]
    22 / 2976 (0.74%)
    19 / 2972 (0.64%)
    18 / 2974 (0.61%)
    20 / 2180 (0.92%)
    16 / 2178 (0.73%)
    12 / 2179 (0.55%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 22
    0 / 19
    0 / 18
    0 / 20
    0 / 16
    0 / 12
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 6
    0 / 4
    0 / 8
    0 / 5
    0 / 5
    0 / 2
    0 / 0
    0 / 0
    HIV infection WHO clinical stage II
         subjects affected / exposed [258]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HIV infection WHO clinical stage III
         subjects affected / exposed [259]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HIV infection WHO clinical stage IV
         subjects affected / exposed [260]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Impetigo
         subjects affected / exposed [261]
    1 / 2976 (0.03%)
    2 / 2972 (0.07%)
    3 / 2974 (0.10%)
    2 / 2180 (0.09%)
    2 / 2178 (0.09%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 3
    0 / 2
    0 / 2
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infected skin ulcer
         subjects affected / exposed [262]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed [263]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injection site abscess
         subjects affected / exposed [264]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injection site cellulitis
         subjects affected / exposed [265]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella sepsis
         subjects affected / exposed [266]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Laryngitis
         subjects affected / exposed [267]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Listeria sepsis
         subjects affected / exposed [268]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Liver abscess
         subjects affected / exposed [269]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lobar pneumonia
         subjects affected / exposed [270]
    6 / 2976 (0.20%)
    5 / 2972 (0.17%)
    7 / 2974 (0.24%)
    8 / 2180 (0.37%)
    9 / 2178 (0.41%)
    7 / 2179 (0.32%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 5
    0 / 7
    0 / 8
    0 / 9
    0 / 7
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed [271]
    2 / 2976 (0.07%)
    3 / 2972 (0.10%)
    6 / 2974 (0.20%)
    0 / 2180 (0.00%)
    4 / 2178 (0.18%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 6
    0 / 0
    0 / 4
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ludwig angina
         subjects affected / exposed [272]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymph node abscess
         subjects affected / exposed [273]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymph node tuberculosis
         subjects affected / exposed [274]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphadenitis bacterial
         subjects affected / exposed [275]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malaria
         subjects affected / exposed [276]
    294 / 2976 (9.88%)
    342 / 2972 (11.51%)
    421 / 2974 (14.16%)
    180 / 2180 (8.26%)
    208 / 2178 (9.55%)
    233 / 2179 (10.69%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 294
    0 / 342
    0 / 421
    0 / 180
    0 / 208
    0 / 233
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 10
    0 / 13
    0 / 11
    0 / 6
    0 / 9
    0 / 4
    0 / 0
    0 / 0
    Mastoiditis
         subjects affected / exposed [277]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Measles
         subjects affected / exposed [278]
    7 / 2976 (0.24%)
    2 / 2972 (0.07%)
    5 / 2974 (0.17%)
    14 / 2180 (0.64%)
    10 / 2178 (0.46%)
    8 / 2179 (0.37%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 2
    0 / 5
    0 / 14
    0 / 10
    0 / 8
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis
         subjects affected / exposed [279]
    5 / 2976 (0.17%)
    5 / 2972 (0.17%)
    1 / 2974 (0.03%)
    2 / 2180 (0.09%)
    3 / 2178 (0.14%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 5
    0 / 1
    0 / 2
    0 / 3
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Meningitis haemophilus
         subjects affected / exposed [280]
    1 / 2976 (0.03%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis meningococcal
         subjects affected / exposed [281]
    3 / 2976 (0.10%)
    2 / 2972 (0.07%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis pneumococcal
         subjects affected / exposed [282]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    Meningitis salmonella
         subjects affected / exposed [283]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    2 / 2180 (0.09%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis tuberculous
         subjects affected / exposed [284]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis viral
         subjects affected / exposed [285]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Moraxella infection
         subjects affected / exposed [286]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mumps
         subjects affected / exposed [287]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mycobacterium ulcerans infection
         subjects affected / exposed [288]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nasopharyngitis
         subjects affected / exposed [289]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oral candidiasis
         subjects affected / exposed [290]
    5 / 2976 (0.17%)
    5 / 2972 (0.17%)
    4 / 2974 (0.13%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 5
    0 / 4
    0 / 1
    0 / 2
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oropharyngeal candidiasis
         subjects affected / exposed [291]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteomyelitis
         subjects affected / exposed [292]
    3 / 2976 (0.10%)
    2 / 2972 (0.07%)
    3 / 2974 (0.10%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 3
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis externa
         subjects affected / exposed [293]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed [294]
    19 / 2976 (0.64%)
    10 / 2972 (0.34%)
    22 / 2974 (0.74%)
    11 / 2180 (0.50%)
    11 / 2178 (0.51%)
    7 / 2179 (0.32%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 19
    0 / 10
    0 / 22
    0 / 11
    0 / 11
    0 / 7
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Otitis media acute
         subjects affected / exposed [295]
    2 / 2976 (0.07%)
    2 / 2972 (0.07%)
    2 / 2974 (0.07%)
    2 / 2180 (0.09%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 2
    0 / 2
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media chronic
         subjects affected / exposed [296]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Parotitis
         subjects affected / exposed [297]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Perineal abscess
         subjects affected / exposed [298]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Periorbital cellulitis
         subjects affected / exposed [299]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peritonitis
         subjects affected / exposed [300]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pharyngitis
         subjects affected / exposed [301]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Plasmodium ovale infection
         subjects affected / exposed [302]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumococcal bacteraemia
         subjects affected / exposed [303]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumococcal sepsis
         subjects affected / exposed [304]
    5 / 2976 (0.17%)
    4 / 2972 (0.13%)
    3 / 2974 (0.10%)
    5 / 2180 (0.23%)
    4 / 2178 (0.18%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 4
    0 / 3
    0 / 5
    0 / 4
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 3
    0 / 0
    0 / 0
    Pneumocystis jirovecii pneumonia
         subjects affected / exposed [305]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    4 / 2180 (0.18%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 4
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed [306]
    202 / 2976 (6.79%)
    215 / 2972 (7.23%)
    223 / 2974 (7.50%)
    217 / 2180 (9.95%)
    206 / 2178 (9.46%)
    202 / 2179 (9.27%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 202
    0 / 215
    0 / 223
    0 / 217
    0 / 206
    0 / 202
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 15
    0 / 7
    0 / 8
    0 / 12
    0 / 15
    0 / 9
    0 / 0
    0 / 0
    Pneumonia pneumococcal
         subjects affected / exposed [307]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia streptococcal
         subjects affected / exposed [308]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia viral
         subjects affected / exposed [309]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Postoperative wound infection
         subjects affected / exposed [310]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pseudomonal sepsis
         subjects affected / exposed [311]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary tuberculosis
         subjects affected / exposed [312]
    7 / 2976 (0.24%)
    1 / 2972 (0.03%)
    4 / 2974 (0.13%)
    6 / 2180 (0.28%)
    6 / 2178 (0.28%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 1
    0 / 4
    0 / 6
    0 / 6
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed [313]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyoderma
         subjects affected / exposed [314]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    3 / 2974 (0.10%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyomyositis
         subjects affected / exposed [315]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    3 / 2974 (0.10%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rabies
         subjects affected / exposed [316]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed [317]
    2 / 2976 (0.07%)
    2 / 2972 (0.07%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rubella
         subjects affected / exposed [318]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Salmonella bacteraemia
         subjects affected / exposed [319]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Salmonella sepsis
         subjects affected / exposed [320]
    36 / 2976 (1.21%)
    34 / 2972 (1.14%)
    42 / 2974 (1.41%)
    25 / 2180 (1.15%)
    34 / 2178 (1.56%)
    37 / 2179 (1.70%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 36
    0 / 34
    0 / 42
    0 / 25
    0 / 34
    0 / 37
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 2
    0 / 1
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    Salmonellosis
         subjects affected / exposed [321]
    1 / 2976 (0.03%)
    3 / 2972 (0.10%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Schistosomiasis
         subjects affected / exposed [322]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed [323]
    33 / 2976 (1.11%)
    27 / 2972 (0.91%)
    43 / 2974 (1.45%)
    23 / 2180 (1.06%)
    15 / 2178 (0.69%)
    13 / 2179 (0.60%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 33
    0 / 27
    0 / 43
    0 / 23
    0 / 15
    0 / 13
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 7
    0 / 4
    0 / 5
    0 / 6
    0 / 5
    0 / 5
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed [324]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Shigella infection
         subjects affected / exposed [325]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin bacterial infection
         subjects affected / exposed [326]
    2 / 2976 (0.07%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin infection
         subjects affected / exposed [327]
    3 / 2976 (0.10%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed [328]
    3 / 2976 (0.10%)
    6 / 2972 (0.20%)
    1 / 2974 (0.03%)
    5 / 2180 (0.23%)
    5 / 2178 (0.23%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 6
    0 / 1
    0 / 5
    0 / 5
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal skin infection
         subjects affected / exposed [329]
    1 / 2976 (0.03%)
    2 / 2972 (0.07%)
    2 / 2974 (0.07%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 2
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Streptococcal infection
         subjects affected / exposed [330]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Streptococcal sepsis
         subjects affected / exposed [331]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    1 / 2180 (0.05%)
    1 / 2178 (0.05%)
    2 / 2179 (0.09%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 2
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Subcutaneous abscess
         subjects affected / exposed [332]
    5 / 2976 (0.17%)
    4 / 2972 (0.13%)
    2 / 2974 (0.07%)
    6 / 2180 (0.28%)
    1 / 2178 (0.05%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 4
    0 / 2
    0 / 6
    0 / 1
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Superinfection
         subjects affected / exposed [333]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Taeniasis
         subjects affected / exposed [334]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tinea capitis
         subjects affected / exposed [335]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tonsillitis
         subjects affected / exposed [336]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    3 / 2974 (0.10%)
    1 / 2180 (0.05%)
    2 / 2178 (0.09%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Toxic shock syndrome
         subjects affected / exposed [337]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tracheobronchitis
         subjects affected / exposed [338]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Trichiniasis
         subjects affected / exposed [339]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tuberculosis
         subjects affected / exposed [340]
    4 / 2976 (0.13%)
    5 / 2972 (0.17%)
    6 / 2974 (0.20%)
    2 / 2180 (0.09%)
    4 / 2178 (0.18%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 5
    0 / 6
    0 / 2
    0 / 4
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    Typhoid fever
         subjects affected / exposed [341]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    3 / 2974 (0.10%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 3
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed [342]
    29 / 2976 (0.97%)
    39 / 2972 (1.31%)
    43 / 2974 (1.45%)
    19 / 2180 (0.87%)
    31 / 2178 (1.42%)
    24 / 2179 (1.10%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 29
    0 / 39
    1 / 43
    0 / 19
    0 / 31
    0 / 24
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed [343]
    22 / 2976 (0.74%)
    23 / 2972 (0.77%)
    28 / 2974 (0.94%)
    11 / 2180 (0.50%)
    15 / 2178 (0.69%)
    22 / 2179 (1.01%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 22
    0 / 23
    0 / 28
    0 / 11
    0 / 15
    0 / 22
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Urinary tract infection bacterial
         subjects affected / exposed [344]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection pseudomonal
         subjects affected / exposed [345]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed [346]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vaginal infection
         subjects affected / exposed [347]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Varicella
         subjects affected / exposed [348]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    2 / 2180 (0.09%)
    1 / 2178 (0.05%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 2
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed [349]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound infection
         subjects affected / exposed [350]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    2 / 2974 (0.07%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound sepsis
         subjects affected / exposed [351]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed [352]
    1 / 2976 (0.03%)
    1 / 2972 (0.03%)
    1 / 2974 (0.03%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Failure to thrive
         subjects affected / exposed [353]
    1 / 2976 (0.03%)
    0 / 2972 (0.00%)
    2 / 2974 (0.07%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperkalaemia
         subjects affected / exposed [354]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    1 / 2178 (0.05%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed [355]
    10 / 2976 (0.34%)
    10 / 2972 (0.34%)
    18 / 2974 (0.61%)
    2 / 2180 (0.09%)
    3 / 2178 (0.14%)
    3 / 2179 (0.14%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 10
    0 / 10
    0 / 18
    0 / 2
    0 / 3
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 3
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed [356]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    1 / 2179 (0.05%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoproteinaemia
         subjects affected / exposed [357]
    0 / 2976 (0.00%)
    2 / 2972 (0.07%)
    1 / 2974 (0.03%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Kwashiorkor
         subjects affected / exposed [358]
    11 / 2976 (0.37%)
    4 / 2972 (0.13%)
    17 / 2974 (0.57%)
    8 / 2180 (0.37%)
    8 / 2178 (0.37%)
    4 / 2179 (0.18%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 11
    0 / 4
    0 / 17
    0 / 8
    0 / 8
    0 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    Malnutrition
         subjects affected / exposed [359]
    27 / 2976 (0.91%)
    27 / 2972 (0.91%)
    21 / 2974 (0.71%)
    20 / 2180 (0.92%)
    30 / 2178 (1.38%)
    19 / 2179 (0.87%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 27
    0 / 27
    0 / 21
    0 / 20
    0 / 30
    0 / 19
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 4
    0 / 3
    0 / 3
    0 / 3
    0 / 3
    0 / 5
    0 / 0
    0 / 0
    Marasmus
         subjects affected / exposed [360]
    6 / 2976 (0.20%)
    8 / 2972 (0.27%)
    4 / 2974 (0.13%)
    6 / 2180 (0.28%)
    5 / 2178 (0.23%)
    7 / 2179 (0.32%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 8
    0 / 4
    0 / 6
    0 / 5
    0 / 7
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 3
    0 / 4
    0 / 2
    0 / 2
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    Metabolic acidosis
         subjects affected / exposed [361]
    0 / 2976 (0.00%)
    0 / 2972 (0.00%)
    0 / 2974 (0.00%)
    1 / 2180 (0.05%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Underweight
         subjects affected / exposed [362]
    0 / 2976 (0.00%)
    1 / 2972 (0.03%)
    0 / 2974 (0.00%)
    0 / 2180 (0.00%)
    0 / 2178 (0.00%)
    0 / 2179 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [15] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [16] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [17] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [18] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [19] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [20] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [21] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [22] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [23] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [24] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [25] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [26] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [27] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [28] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [29] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [30] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [31] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [32] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [33] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [34] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [35] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [36] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [37] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [38] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [39] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [40] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [41] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [42] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [43] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [44] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [45] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [46] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [47] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [48] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [49] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [50] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [51] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [52] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [53] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [54] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [55] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [56] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [57] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [58] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [59] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [60] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [61] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [62] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [63] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [64] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [65] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [66] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [67] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [68] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [69] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [70] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [71] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [72] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [73] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [74] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [75] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [76] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [77] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [78] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [79] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [80] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [81] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [82] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [83] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [84] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [85] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [86] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [87] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [88] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [89] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [90] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [91] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [92] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [93] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [94] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [95] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [96] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [97] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [98] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [99] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [100] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [101] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [102] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [103] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [104] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [105] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [106] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [107] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [108] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [109] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [110] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [111] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [112] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [113] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [114] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [115] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [116] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [117] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [118] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [119] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [120] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [121] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [122] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [123] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [124] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [125] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [126] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [127] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [128] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [129] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [130] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [131] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [132] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [133] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [134] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [135] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [136] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [137] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [138] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [139] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [140] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [141] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [142] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [143] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [144] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [145] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [146] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [147] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [148] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [149] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [150] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [151] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [152] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [153] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [154] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [155] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [156] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [157] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [158] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [159] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [160] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [161] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [162] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [163] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [164] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [165] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [166] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [167] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [168] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [169] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [170] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [171] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [172] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [173] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [174] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [175] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [176] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [177] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [178] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [179] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [180] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [181] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [182] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [183] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [184] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [185] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [186] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [187] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [188] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [189] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [190] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [191] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [192] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [193] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [194] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [195] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [196] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [197] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [198] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [199] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [200] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [201] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [202] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [203] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [204] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [205] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [206] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [207] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [208] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [209] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [210] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [211] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [212] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [213] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [214] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [215] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [216] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [217] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [218] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [219] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [220] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [221] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [222] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [223] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [224] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [225] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [226] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [227] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [228] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [229] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [230] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [231] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [232] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [233] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [234] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [235] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [236] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [237] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [238] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [239] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [240] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [241] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [242] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [243] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [244] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [245] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [246] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [247] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [248] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [249] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [250] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [251] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [252] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [253] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [254] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [255] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [256] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [257] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [258] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [259] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [260] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [261] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [262] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [263] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [264] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [265] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [266] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [267] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [268] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [269] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [270] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [271] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [272] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [273] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [274] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [275] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [276] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [277] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [278] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [279] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [280] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [281] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [282] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [283] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [284] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [285] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [286] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [287] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [288] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [289] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [290] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [291] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [292] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [293] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [294] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [295] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [296] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [297] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [298] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [299] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [300] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [301] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [302] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [303] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [304] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [305] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [306] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [307] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [308] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [309] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [310] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [311] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [312] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [313] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [314] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [315] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [316] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [317] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [318] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [319] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [320] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [321] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [322] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [323] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [324] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [325] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [326] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [327] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [328] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [329] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [330] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [331] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [332] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [333] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [334] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [335] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [336] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [337] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [338] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [339] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [340] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [341] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [342] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [343] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [344] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [345] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [346] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [347] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [348] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [349] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [350] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [351] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [352] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [353] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [354] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [355] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [356] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [357] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [358] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [359] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [360] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [361] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [362] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    R3R (5-17M) Group R3C (5-17M) Group C3C (5-17M) Group R3R (6-12W) Group R3C (6-12W) Group C3C (6-12W) Group RTS,S/AS01 (5-17M) Group RTS,S/AS01 (6-12W) Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    233 / 2976 (7.83%)
    205 / 2972 (6.90%)
    626 / 2974 (21.05%)
    231 / 2180 (10.60%)
    239 / 2178 (10.97%)
    600 / 2179 (27.54%)
    1273 / 1479 (86.07%)
    1161 / 1462 (79.41%)
    General disorders and administration site conditions
    Pain – PRI
    alternative assessment type: Systematic
         subjects affected / exposed [363]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    105 / 721 (14.56%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    342 / 738 (46.34%)
    401 / 1479 (27.11%)
    705 / 1462 (48.22%)
         occurrences all number
    0
    0
    105
    0
    0
    342
    401
    705
    Redness – PRI
    alternative assessment type: Systematic
         subjects affected / exposed [364]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    49 / 721 (6.80%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    163 / 738 (22.09%)
    122 / 1479 (8.25%)
    292 / 1462 (19.97%)
         occurrences all number
    0
    0
    49
    0
    0
    163
    122
    292
    Swelling – PRI
    alternative assessment type: Systematic
         subjects affected / exposed [365]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    119 / 721 (16.50%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    248 / 738 (33.60%)
    303 / 1479 (20.49%)
    427 / 1462 (29.21%)
         occurrences all number
    0
    0
    119
    0
    0
    248
    303
    427
    Pain – BST
    alternative assessment type: Systematic
         subjects affected / exposed [366]
    109 / 641 (17.00%)
    45 / 639 (7.04%)
    41 / 633 (6.48%)
    59 / 608 (9.70%)
    29 / 625 (4.64%)
    25 / 621 (4.03%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    109
    45
    41
    59
    29
    25
    0
    0
    Swelling – BST
    alternative assessment type: Systematic
         subjects affected / exposed [367]
    42 / 641 (6.55%)
    35 / 639 (5.48%)
    30 / 633 (4.74%)
    45 / 608 (7.40%)
    28 / 625 (4.48%)
    43 / 621 (6.92%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    42
    35
    30
    45
    28
    43
    0
    0
    Drowsiness - PRI
    alternative assessment type: Systematic
         subjects affected / exposed [368]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    78 / 721 (10.82%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    121 / 738 (16.40%)
    230 / 1479 (15.55%)
    285 / 1462 (19.49%)
         occurrences all number
    0
    0
    78
    0
    0
    121
    230
    285
    Irritability – PRI
    alternative assessment type: Systematic
         subjects affected / exposed [369]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    96 / 721 (13.31%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    244 / 738 (33.06%)
    369 / 1479 (24.95%)
    574 / 1462 (39.26%)
         occurrences all number
    0
    0
    96
    0
    0
    244
    369
    574
    Loss of appetite - PRI
    alternative assessment type: Systematic
         subjects affected / exposed [370]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    132 / 721 (18.31%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    104 / 738 (14.09%)
    398 / 1479 (26.91%)
    243 / 1462 (16.62%)
         occurrences all number
    0
    0
    132
    0
    0
    104
    398
    243
    Fever (axillary temperature ≥37.5°C) - PRI
    alternative assessment type: Systematic
         subjects affected / exposed [371]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    235 / 721 (32.59%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    331 / 738 (44.85%)
    897 / 1479 (60.65%)
    839 / 1462 (57.39%)
         occurrences all number
    0
    0
    235
    0
    0
    331
    897
    839
    Drowsiness – BST
    alternative assessment type: Systematic
         subjects affected / exposed [372]
    55 / 641 (8.58%)
    22 / 639 (3.44%)
    21 / 633 (3.32%)
    33 / 608 (5.43%)
    19 / 625 (3.04%)
    15 / 621 (2.42%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    55
    22
    21
    33
    19
    15
    0
    0
    Irritability – BST
    alternative assessment type: Systematic
         subjects affected / exposed [373]
    63 / 641 (9.83%)
    25 / 639 (3.91%)
    18 / 633 (2.84%)
    46 / 608 (7.57%)
    23 / 625 (3.68%)
    23 / 621 (3.70%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    63
    25
    18
    46
    23
    23
    0
    0
    Loss of appetite – BST
    alternative assessment type: Systematic
         subjects affected / exposed [374]
    66 / 641 (10.30%)
    27 / 639 (4.23%)
    21 / 633 (3.32%)
    45 / 608 (7.40%)
    27 / 625 (4.32%)
    18 / 621 (2.90%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    66
    27
    21
    45
    27
    18
    0
    0
    Fever (axillary temperature ≥37.5°C) - BST
    alternative assessment type: Systematic
         subjects affected / exposed [375]
    233 / 641 (36.35%)
    70 / 639 (10.95%)
    45 / 633 (7.11%)
    152 / 608 (25.00%)
    52 / 625 (8.32%)
    58 / 621 (9.34%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    233
    70
    45
    152
    52
    58
    0
    0
    Pyrexia – PRI
         subjects affected / exposed [376]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    67 / 721 (9.29%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    112 / 738 (15.18%)
    200 / 1479 (13.52%)
    251 / 1462 (17.17%)
         occurrences all number
    0
    0
    67
    0
    0
    112
    200
    251
    Pyrexia - BST
         subjects affected / exposed [377]
    44 / 641 (6.86%)
    10 / 639 (1.56%)
    7 / 633 (1.11%)
    12 / 608 (1.97%)
    11 / 625 (1.76%)
    39 / 621 (6.28%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    44
    10
    7
    12
    11
    39
    0
    0
    Gastrointestinal disorders
    Diarrhoea - PRI
         subjects affected / exposed [378]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    88 / 721 (12.21%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 738 (0.00%)
    188 / 1479 (12.71%)
    0 / 1462 (0.00%)
         occurrences all number
    0
    0
    88
    0
    0
    0
    188
    0
    Respiratory, thoracic and mediastinal disorders
    Cough - PRI
         subjects affected / exposed [379]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    41 / 721 (5.69%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 738 (0.00%)
    107 / 1479 (7.23%)
    0 / 1462 (0.00%)
         occurrences all number
    0
    0
    41
    0
    0
    0
    107
    0
    Infections and infestations
    Conjunctivitis – PRI
         subjects affected / exposed [380]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    64 / 721 (8.88%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    63 / 738 (8.54%)
    111 / 1479 (7.51%)
    118 / 1462 (8.07%)
         occurrences all number
    0
    0
    64
    0
    0
    63
    111
    118
    Enteritis – PRI
         subjects affected / exposed [381]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    62 / 721 (8.60%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    72 / 738 (9.76%)
    124 / 1479 (8.38%)
    131 / 1462 (8.96%)
         occurrences all number
    0
    0
    62
    0
    0
    72
    124
    131
    Gastroenteritis- PRI
         subjects affected / exposed [382]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    170 / 721 (23.58%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    131 / 738 (17.75%)
    372 / 1479 (25.15%)
    220 / 1462 (15.05%)
         occurrences all number
    0
    0
    170
    0
    0
    131
    372
    220
    Malaria- PRI
         subjects affected / exposed [383]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    173 / 721 (23.99%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    70 / 738 (9.49%)
    265 / 1479 (17.92%)
    137 / 1462 (9.37%)
         occurrences all number
    0
    0
    173
    0
    0
    70
    265
    137
    Nasopharyngitis – PRI
         subjects affected / exposed [384]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    58 / 721 (8.04%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    55 / 738 (7.45%)
    115 / 1479 (7.78%)
    76 / 1462 (5.20%)
         occurrences all number
    0
    0
    58
    0
    0
    55
    115
    76
    Pneumonia – PRI
         subjects affected / exposed [385]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    71 / 721 (9.85%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    39 / 738 (5.28%)
    166 / 1479 (11.22%)
    86 / 1462 (5.88%)
         occurrences all number
    0
    0
    71
    0
    0
    39
    166
    86
    Rhinitis – PRI
         subjects affected / exposed [386]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 721 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    75 / 738 (10.16%)
    0 / 1479 (0.00%)
    148 / 1462 (10.12%)
         occurrences all number
    0
    0
    0
    0
    0
    75
    0
    148
    Upper respiratory tract infection – PRI
         subjects affected / exposed [387]
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    326 / 721 (45.21%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    312 / 738 (42.28%)
    638 / 1479 (43.14%)
    584 / 1462 (39.95%)
         occurrences all number
    0
    0
    326
    0
    0
    312
    638
    584
    Malaria - BST
         subjects affected / exposed [388]
    49 / 641 (7.64%)
    53 / 639 (8.29%)
    84 / 633 (13.27%)
    34 / 608 (5.59%)
    29 / 625 (4.64%)
    40 / 621 (6.44%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    49
    53
    84
    34
    29
    40
    0
    0
    Upper respiratory tract infection – BST
         subjects affected / exposed [389]
    61 / 641 (9.52%)
    55 / 639 (8.61%)
    55 / 633 (8.69%)
    44 / 608 (7.24%)
    56 / 625 (8.96%)
    55 / 621 (8.86%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    61
    55
    55
    44
    56
    55
    0
    0
    Gastroenteritis - BST
         subjects affected / exposed [390]
    17 / 641 (2.65%)
    16 / 639 (2.50%)
    13 / 633 (2.05%)
    231 / 608 (37.99%)
    239 / 625 (38.24%)
    240 / 621 (38.65%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    16
    13
    231
    239
    240
    0
    0
    Notes
    [363] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [364] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [365] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [366] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [367] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [368] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [369] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [370] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [371] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [372] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [373] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [374] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [375] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [376] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [377] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [378] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [379] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [380] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [381] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [382] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [383] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [384] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [385] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [386] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [387] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [388] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [389] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.
    [390] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: Number of subject exposed for this AE is as per number of subjects actually exposed to this AE taking into account its type (SAE vs AE), the period of assessment considered and based on subjects with available results. In case subjects exposed per group are marked as totalling 1, it means the group considered was not applicable for the specified AE/period considered.

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Aug 2008
    The primary objective and endpoint were updated to make them case-driven. The number of episodes needed to have sufficient power and precision to evaluate the primary endpoint was added to the protocol. In the original protocol, malaria episodes occurring within 28 days of a previous episode were excluded from the analysis, to avoid including recrudescence of the first infection. However, since writing the protocol, all sites switched to highly effective first line therapy with artemisin combinations and recrudescence were rare. Therefore, the period of exclusion was reduced to 14 days to reflect the half-lives of these new therapeutic regimens and consequently the shorter period of time for which individuals were non-susceptible after anti-malarial therapy.
    24 Oct 2008
    RTS protein is derived from a sporozoite surface antigen of the Plasmodium falciparum strain NF54. Previous studies showed that protection was not limited to the NF54 parasite genotype. As part of Amendment 2, the collection of study samples for the determination of parasite genotyping to evaluate strain-specific efficacy and protection against infection due to multiple strains was added.
    26 Nov 2009
    Based on a theoretical concern that the use of new adjuvanted vaccines could promote a rupture of immunological self-tolerance, regulatory authorities required optimizing the data collection on immune-mediated diseases (IMD). As a result, GSK Biologicals decided to define IMD as adverse events of interest and to optimize auto-immunity data collection processes in studies of all GSK’s adjuvanted candidate vaccines. The protocol was adapted accordingly. The assessment of all unsolicited adverse events (AEs) in the first 200 subjects enrolled in each age category and at each study site was added in Amendment 3. The assessment of serious adverse events (SAEs) occurring within 30 days of each vaccination dose was added to the protocol in order to better assess any temporal relationship between SAE occurrence and variation across all studies performed at GSK Biologicals. The exclusion criterion on anemia was clarified by splitting the information over two lines. Anemia was defined as hemoglobin < 5.0 g/dL or or hemoglobin < 8 g/dL associated with clinical signs of heart failure or severe respiratory distress.
    01 Dec 2010
    This amendment 4 was done to increase the follow up period of the study. All subjects having their Visit 34 before and including on 30 September 2013 will be followed up. Due to the wide range of enrolment, there will be a variable number of months of follow-up after vaccination for individual children. Based on the actual enrolment, the mean follow-up time will be 49 months post Dose 1 (range: 41-55) for the 5 to 17 months age category and 41 months post Dose 1 (range: 32-48) for the 6 to 12 weeks age category. The protocol was amended to collect data on severe malaria; malaria hospitalization and parasite prevalence in the 11 participating centers using the same methodologies and case definitions as in the primary trial phase. Occurrence of SAEs will be monitored in all 11 centers. Surveillance for clinical malaria will take place in at least 3 centers with varying transmission levels. Immunogenicity endpoints will also be collected on a subset of individuals from both age categories in at least these 3 centers.
    23 Jan 2012
    Amendment 5 was developed to include an analysis time point at Month 20 (18 months post Dose 3). No changes have been made to the protocol endpoints or statistical methods but the protocol endpoints will be analyzed on data collected up to Month 20 as soon as these data are available. The rationale is to have the full scope of protocol defined efficacy and safety endpoints related to a primary schedule without booster in both age categories followed up for 20 months earlier than at study end (Visit 34) as initially planned. The detailed analysis of gender-specific vaccine efficacy will be reported in full at the end of the study (Visit 34). Also, the text related to the recording of concomitant medication was adapted to allow more flexibility in the collection of data on concomitant medication during the study.
    08 Aug 2012
    Amendment 6 was developed related to that, at a request from the European Medicines Agency’s (EMA), GSK Biologicals has updated its procedure for emergency unblinding during the conduct of a clinical study. According to the revised procedure, the responsibility and the decision to break the treatment code in emergency situations resides solely with the investigator and consequently, the investigator will have full authority to break the treatment code. Investigators will be granted an unrestricted, immediate and direct access to the individual treatment codes via an automated system.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 00:17:56 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA